Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of HBMMSC Injection in the Treatment of APAP

NCT06111846 is registered in ClinicalTrials.gov with Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. as lead sponsor.

NCT NCT06111846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06111846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of HBMMSC Injection in the Treatment of APAP
Lead sponsor
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 25, 2023
Completion date
August 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune pulmonary alveolar proteinosis